⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13039773 | 0.75 | — | — | |
| SCHEMBL7587650 | 0.75 | — | — | |
| SCHEMBL12336186 | 0.75 | — | — | |
| SCHEMBL20098013 | 0.74 | CA1 (0.30) | — | |
| SCHEMBL14617059 | 0.73 | — | — | |
| SCHEMBL22485422 | 0.71 | — | — | |
| SCHEMBL15044679 | 0.71 | — | — | |
| SCHEMBL9720660 | 0.71 | — | — | |
| SCHEMBL19507003 | 0.69 | CA12 (0.34) | — | |
| SCHEMBL8473650 | 0.69 | TSHR (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018080-B2 | Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway | THE BROAD INSTITUTE, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240018552-A1 | NOVEL CRISPR ENZYMES AND SYSTEMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2024-01-18 | — | — | US | disclosed |
| US-10022455-B2 | Biodegradable lipids for delivery of nucleic acids | TRANSLATE BIO, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170281542-A1 | LIPID FORMULATIONS FOR DELIVERY OF MESSENGER RNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2017-10-05 | — | — | US | disclosed |
| US-20170246319-A1 | BIODEGRADABLE LIPIDS FOR DELIVERY OF NUCLEIC ACIDS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2017-08-31 | — | — | US | disclosed |
| US-9663492-B2 | Methods for the preparation of charged crosslinkers | IMMUNOGEN, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9629804-B2 | Lipid formulations for delivery of messenger RNA | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160272616-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | IMMUNOGEN, INC. | 2016-09-22 | — | — | US | disclosed |
| US-9242936-B2 | Methods for the preparation of charged crosslinkers | IMMUNOGEN, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150166482-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | IMMUNOGEN, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150140070-A1 | LIPID FORMULATIONS FOR DELIVERY OF MESSENGER RNA | TRANSLATE BIO, INC. | 2015-05-21 | — | — | US | disclosed |
| US-8921566-B2 | Methods for the preparation of charged crosslinkers | IMMUNOGEN, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140135502-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | IMMUNOGEN, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20120165537-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | IMMUNOGEN, INC. (US) | 2012-06-28 | — | — | US | disclosed |